RxDoctor Payments Data

David Vu, MD

Family Medicine · Oklahoma City, OKNPI 1851367999

Payments from drug & device makers

$2,077in general payments, 2019–2025

Across 115 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$592
  • Boehringer Ingelheim$261
  • AbbVie$224
  • AstraZeneca$155
  • Sanofi-aventis U.S. LLC$97
  • GSK$75
  • plus $673 from 20 others

What the payments were for

  • Food & beverage$2,077100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,077 in reported general payments places this provider in the 70th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$49,877
Medicare patients
100
Services billed
702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$98,257
Trelegy ElliptaFluticasone/Umeclidin/Vilanter128$88,913
MounjaroTirzepatide57$77,725
OzempicSemaglutide34$47,684
JardianceEmpagliflozin38$42,502
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,346$41,387
JanuviaSitagliptin Phosphate41$39,631
GlyxambiEmpagliflozin/Linagliptin26$33,434
XareltoRivaroxaban28$32,237
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog68$31,372
Tresiba Flextouch U-200Insulin Degludec30$26,976
TradjentaLinagliptin21$22,849
JanumetSitagliptin Phos/Metformin Hcl12$13,744
Tresiba Flextouch U-100Insulin Degludec26$13,278
FarxigaDapagliflozin Propanediol12$12,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Spiriva Respimat, Stiolto Respimat$261$124,455124 claims
PfizerEliquis$20$98,25797 claims
GSKTrelegy Ellipta$75$88,913128 claims
Lilly USA, LLCMounjaro$56$77,72557 claims
Novo NordiskOzempic$592$47,68434 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$155$30,89454 claims
Sumitomo Pharma America, Inc.Gemtesa$26$10,82918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →